Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?
Standard
Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? / Bielack, S S; Erttmann, Rudolf; Kempf-Bielack, B; Winkler, K.
in: EUR J CANCER, Jahrgang 32, Nr. 10, 10, 1996, S. 1652-1660.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
Bielack, SS, Erttmann, R, Kempf-Bielack, B & Winkler, K 1996, 'Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?', EUR J CANCER, Jg. 32, Nr. 10, 10, S. 1652-1660. <http://www.ncbi.nlm.nih.gov/pubmed/8983270?dopt=Citation>
APA
Bielack, S. S., Erttmann, R., Kempf-Bielack, B., & Winkler, K. (1996). Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? EUR J CANCER, 32(10), 1652-1660. [10]. http://www.ncbi.nlm.nih.gov/pubmed/8983270?dopt=Citation
Vancouver
Bielack SS, Erttmann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? EUR J CANCER. 1996;32(10):1652-1660. 10.
Bibtex
@article{0efc8c3b5a384dd589f59819241a2b1c,
title = "Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?",
author = "Bielack, {S S} and Rudolf Erttmann and B Kempf-Bielack and K Winkler",
year = "1996",
language = "Deutsch",
volume = "32",
pages = "1652--1660",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "10",
}
RIS
TY - JOUR
T1 - Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?
AU - Bielack, S S
AU - Erttmann, Rudolf
AU - Kempf-Bielack, B
AU - Winkler, K
PY - 1996
Y1 - 1996
M3 - SCORING: Zeitschriftenaufsatz
VL - 32
SP - 1652
EP - 1660
JO - EUR J CANCER
JF - EUR J CANCER
SN - 0959-8049
IS - 10
M1 - 10
ER -
